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Abstract
Worldwide, sickle cell trait is a highly prevalent gene carrier state. While generally a benign 
condition with a normal life expectancy, it is becoming increasingly clear that the sickle trait is 
associated with certain adverse outcomes. This article will focus on three of these outcomes, 
namely exertional rhabdomyolysis and sudden death, chronic renal dysfunction, and venous 
thromboembolism. In each case, the epidemiological evidence for the association is reviewed, 
together with the existing data on potential underlying mechanisms. Because newborn screening 
programmes for sickle cell anaemia also identify those with sickle cell trait, it is imperative that 
further studies determine what, if any, preventive measures can be taken to reduce the burden of 
these uncommon but potentially morbid complications in affected individuals.
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Introduction
1.1 Epidemiology of sickle cell trait
It is estimated that 300 million people worldwide are heterozygous for the mutation in the 
HBB gene (HBB E6V, also termed HbS mutation or ’sickle gene’) that results in sickle cell 
anaemia (SCA), and are said to have sickle cell trait (SCT). In the overwhelming majority of 
cases, SCT is a benign entity associated with a normal life expectancy (Stark, et al 1980). 
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However, the purpose of this article is to review the most contemporary data on potential 
adverse outcomes that can be associated with SCT.
The sickle cell mutation arose and remained evolutionarily conserved in those parts of the 
world where malaria is or was once highly endemic, including sub-Saharan Africa, parts of 
the Mediterranean, the Middle East and India. Within these regions, the prevalence of SCT 
may vary widely, with pockets of very high prevalence (30% or more) corresponding to high 
loco-regional malaria burdens. This striking association was first reported by Allison in a 
landmark study in Kenya 60 years ago (Allison 1954). The evolutionary advantage afforded 
by SCT is presumably related to the fact that, although carriers are not protected from 
parasitaemia when exposed to falciparum malaria, they are about 90% less likely to suffer 
the severe consequences of infection (May, et al 2007, Williams, et al 2005a). The precise 
mechanism(s) by which SCT confers this protective effect in red blood cells (RBCs) remains 
a topic of active research. Possibilities that have been invoked include; 1] blunting of 
intracellular parasite growth; 2] abnormal trafficking, expression and display of parasite 
virulence factors on host RBCs; 3] activation of the innate immune system and enhanced 
acquisition of adaptive immunity to malaria; and/or 4] enhanced clearance of parasitized 
RBCs (Gong, et al 2012, Taylor, et al 2013, Williams, et al 2005b).
The HbS concentration in SCT may demonstrate considerable variability. While typically in 
the range of 42%, it has been shown to have a trimodal distribution in the African-American 
population, caused by the interaction with α-thalassaemia. Up to 30% of this population 
possesses a deletion of one α-globin gene (-α/αα), ωηereas about 2% of the population is 
homozygous (-α/−α) for the deletion. The HbS levels in these individuals are more typically 
around 37% and 29%, respectively (Steinberg and Embury 1986). Interestingly, despite the 
fact that both SCT and α-thalassaemia are individually protective against severe falciparum 
malaria, the protection is lost when both conditions are inherited together (Williams, et al 
2005b).
The slave trade trafficking and population migrations in recent centuries led to the 
dissemination of the sickle gene to other parts of the world. In the United States, for 
example, 6-9% of the African-American population and 0.01-0.05% of other racial/ethnic 
groups, equating to an estimated 3 million persons, are carriers of the sickle gene. In the 
French Caribbean Islands, such as Guadeloupe and Martinique, 6-7% of the population has 
SCT.
1.2. History of research in SCT
The history of research into adverse outcomes associated with SCT has a rather long and 
sometimes troubled history. In 1971, then President Richard Nixon declared a ‘war on sickle 
cell disease’. The following year, partly in response to the widely held opinion that subjects 
with SCT were suffering multiple adverse outcomes, the U.S. Congress passed the National 
Sickle Cell Anemia Control Act. This Act stated that “efforts to prevent sickle cell anemia 
must be directed toward increased research....and the education, screening and counseling of 
carriers of the sickle cell trait”. The majority of the allocated funds however were spent on 
mass screening of African-Americans (which was intended to be voluntary), rather than 
research. In addition, there were no provisions to facilitate counselling, and there was 
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widespread misinformation about the distinction between SCA and SCT (Beutler, et al 
1971, Sullivan 1987). This unfortunate episode had two major negative impacts: first, many 
additional studies appeared in the literature purporting to show an association between 
multiple co-morbidities and SCT (Johnson 1982). However, the conclusions were often 
flawed, due to a combination of inaccurate diagnostic approaches and/or erroneous 
statistical considerations (Gima and Bemis 1975, Heller 1973). The other major effect of this 
screening programme was to promote occupational discrimination, inflation of health and 
life insurance premiums, and even occasional reports of medically recommended 
sterilization for individuals with SCT. As a result of the confusion and inauspicious 
consequences of the screening programmes, there were calls to limit further research on 
SCT (Culliton 1972, Gima 1975).
1.3. Contemporary areas of research focus in SCT
With the advent of more sophisticated tools and clinical study designs, the opportunity to re-
examine whether SCT is associated with adverse health outcomes has prompted a renewed 
interest in this topic. The National Heart, Lung, and Blood Institute (NHLBI) of the National 
Institutes for Health (NIH) recently convened a roundtable to review existing evidence and 
determine future research priorities in SCT (Goldsmith, et al 2012). A similar workshop also 
took place at the Centers for Disease Control (Grant, et al 2011). It was recommended that 
“a more methodologically sophisticated approach” to defining adverse outcomes was 
required, and that research into complications, such as those resulting in thrombosis and 
renal abnormalities, should be complemented by appropriate ethical, social and behavioral 
research (Goldsmith, et al 2012).
The remainder of this review will focus on three conditions in which the association with 
SCT is now increasingly well established, including exertional rhabdomyolysis and sudden 
death, renal disease and venous thromboembolism (VTE).
2. Exercise-related complications in SCT carriers
2.1. The military experience
Numerous case studies have reported exercise-related death in subjects with SCT over the 
past 5 decades. One of the earliest (Jones, et al 1970) described metabolic acidosis, 
hyperkalaemia and a kind of “sickle cell crisis” in a carrier that occurred abruptly after 
running 1 mile at mild altitude. Zimmerman et al (1974) described the case of an individual 
with SCT who developed rhadomyolysis and myoglobinuria after running 3 miles and died 
65 hours later. Greater attention was focused on this association following the publication of 
a large epidemiological study that retrospectively evaluated the risk of exercise-related death 
in U.S. Armed Forces recruits over a 5-year period (1977-1981) (Kark, et al 1987). The 
relative risk of exercise-related death explained by pre-existing disease (largely silent heart 
disease) was 2.3 for SCT, which was not statistically significant. In contrast, the relative risk 
of exercise-related death unexplained by pre-existing disease was 28 for SCT subjects (95% 
confidence interval [CI], 9-100; p<0.001). The timing of exercise-related complications in 
SCT has generally been linked to the immediate stress of exercise. About 50% of the deaths 
resulted from heat illness from overexertion, while the remaining cases were classified as 
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‘idiopathic’. Poor physical conditioning of recruits and dehydration appeared to increase the 
risk for adverse events during exercise (Kark, et al 1987, Kark and Ward 1994, O'Connor, et 
al 2012).
2.2. The athlete experience
Exercise-related death has also been described in athletes with SCT (Dincer and Raza 2005, 
Eichner 2010, Harris, et al 2012, Kerle and Runkle 1996). Harmon et al (2011) reviewed the 
causes of all cases of sudden death in student-athletes from the National Collegiate Athletic 
Association (NCAA) in the U.S. between January 2004 and December 2008. 72 deaths 
occurred in (American) football players due to trauma unrelated to sports activities or 
medical causes. Of the 20 deaths due to medical causes, 13 occurred during exertion; these 
cases were in turn accounted for by cardiac disease (n=6; 46%), SCT (n=5; 39%) and heat 
stroke unrelated to SCT (n=2; 15%). All deaths associated with SCT occurred in African-
American Division I football players. The overall risk of exertional death from any cause 
was 5.2 times higher in African-American players with or without SCT compared with that 
in non African-American football players. The calculated relative risk of exertional death in 
all Division I football players (i.e. all ethnicities) with SCT was 1:827, which represented a 
37-fold higher relative risk than in athletes without SCT. The relative risk of exertional 
death in African-American Division I football players with SCT was 22 times greater than in 
those without SCT (Harmon, et al 2012). It has been suggested that the repetition of very 
intense exercise with incomplete recovery during football training sessions results in 
massive sickling and rhabdomyolysis leading to death in affected individuals (Eichner 
2014).
2.3. Physiology and possible pathophysiological mechanisms in subjects with SCT
Although epidemiological studies suggest that SCT may be a risk factor for exercise-related 
death, it is very difficult to prove a cause-effect relationship. In patients with SCA, anaemia, 
haemolysis, impaired blood rheology, decreased nitric oxide bioavailability, impaired 
vascular function, activation of coagulation and inflammation, oxidative stress and vascular 
adhesive phenomena play a role in the occurrence of acute vaso-occlusive events and the 
development of vasculopathy and chronic organ damage (Kato, et al 2007). Indeed, several 
studies have measured biomarkers of these processes in exercising SCT carriers during 
various protocols lasting from 1 to 40 min. Briefly, exercise in SCT results in: 1) a slight 
decrease of RBC deformability, with or without evidence of sickled RBCs in the circulation 
(Martin, et al 1989, Tripette, et al 2010a); 2) a moderate to marked increase of whole blood 
viscosity (Diaw, et al 2013a, Tripette, et al 2010a); 3) oxidative stress (Faes, et al 2014); 
and 4) evidence of systemic inflammation (Monchanin, et al 2007, Tripette, et al 2010b). 
Although these biological responses can also be found in non-SCT subjects, they appear to 
be exaggerated in individuals with SCT. Whether these abnormalities are capable of 
triggering vaso-occlusive-like episodes is unknown. However, the magnitude of the 
biological responses induced by physical stress in SCT is far less than that observed on a 
chronic basis in patients with SCA, especially during painful vaso-occlusive crises. 
Nevertheless, a few of these biomarkers, such as blood viscosity, could be of potential 
clinical relevance. Depending on the underlying vascular function, increased blood viscosity 
could result in increased vascular resistance and impaired blood flow (Tripette, et al 2013, 
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Vincent, et al 2010). Notably, increased blood viscosity has also been identified as a risk 
factor for vaso-occlusive crisis in patients with SCA (Lamarre, et al 2012, Nebor, et al 
2011). Individuals with SCT usually manifest higher blood viscosity than those without the 
gene at rest (Tripette, et al 2009). In the general population, exercise causes a rise of blood 
viscosity as a consequence of the increase of haematocrit and plasma viscosity and the 
changes in RBC rheological properties (i.e., deformability and aggregation). Exercise also 
leads to a rise of blood viscosity in SCT with an increase that is more pronounced than in 
healthy individuals, particularly in subjects who are dehydrated (Diaw, et al 2013b, Tripette, 
et al 2010c). Theoretically, this amplified response could increase the risks for end organ 
perfusion disorders in SCT, but only when vascular reactivity is blunted. Vascular function 
has been poorly studied in SCT, but recent findings suggest that vascular reserve could be 
slightly decreased compared to non-carriers at rest (Tripette, et al 2013). However, no study 
has investigated vascular function in SCT during exercise. Further studies using 
appropriately sensitive techniques on large cohorts are needed to characterize vascular 
function in carriers during exercise.
2.4. Potential approaches to prevent SCT-associated sudden death
The participants in the NHLBI workshop noted that “the reported deaths in NCAA Division 
I athletes all occurred during conditioning, not during game play, either in sprinting or speed 
drills, and in one case with weight lifting” (Goldsmith, et al 2012). It was proposed that a 
sickling syndrome could be responsible for vaso-occlusion within exercising skeletal 
muscle, ultimately leading to rhabdomyolysis. However, it was noted that the proof of such 
a mechanism is still lacking, and alternative causes, such as the presence of other gene 
defects that could predispose SCT (or non-SCT) carriers to exercise-induced 
rhabdomyolysis, should be considered (Deuster, et al 2013, Goldsmith, et al 2012, 
O'Connor, et al 2012).
It has been proposed that universally applied precautions, such as longer breaks during 
practice, more frequent hydration, and shortening the intensity and duration of exercise -- 
particularly in hot weather or at high altitude -- should be sufficient to decrease the risks of 
adverse events in all situations involving intense exercise (Goldsmith, et al 2012). In 
applying such precautions to all participants, such a strategy would obviate the need for 
screening for SCT, a practice that could lead to negative discriminatory consequences. This 
position was endorsed by the Sickle Cell Disease Association of America (SCDAA) and the 
American Society of Hematology (http://www.sicklecelldisease.org/index.cfm?page=sickle-
cell-trait-athletics; Eichner 2012; http://www.hematology.org/Advocacy/Statements/
2650.aspx). In contrast, the NCAA proposed to implement systematic screening for SCT in 
student-athletes, with the expressed goal of targeting educational efforts on approaches to 
reduce the risk of serious complications to coaches and affected individuals (Tarini, et al 
2012). The legislation requiring SCT screening in incoming Division I athletes was adopted 
in 2010, and has since been adopted also in Division II and III athletic programmes, albeit 
with some resultant controversy (Bonham, et al 2010, Jordan, et al 2011, O'Connor, et al 
2012). Alternatively, athletes may show proof of prior testing or sign a waiver releasing an 
institution from liability (http://www.nata.org/sites/default/files/
SickleCellTraitAndTheAthlete.pdf).
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In fact, in the absence of a sound understanding of the mechanism(s) of the complications, 
the optimal strategy to reduce the risks for exercise-related death in SCT carriers is 
unknown. Promoting active hydration during exercise is likely to be beneficial (Kark and 
Ward 1994), as adequate hydration does normalize blood viscosity in SCT during exercise 
(Diaw, et al 2013a, Tripette, et al 2010a). Moreover, comparisons of sedentary with trained 
SCT subjects showed that the former group exhibited exaggerated inflammatory and 
oxidative stress responses during exercise, as well as higher blood viscosity (Aufradet, et al 
2010, Chirico, et al 2012, Kark and Ward 1994). Indeed, achieving a high degree of physical 
fitness probably helps carriers to better tolerate unaccustomed strenuous exercise during 
training periods (O'Connor, et al 2012). In a subsequent roundtable organized by the 
American College of Sports Medicine (ACSM) and the Consortium for Health and Military 
Performance (CHAMP), it was emphasized that SCT military recruits at highest risk are 
those who have repeatedly had difficulty passing the Army Physical Fitness Tests 
(O'Connor, et al 2012). Here again, the consensus was that prior to fitness testing, military 
leaders should ensure that recruits are adequately hydrated and rested in a shaded or indoor 
cooled environment (O'Connor, et al 2012). In addition, a minimum of 48 h should elapse 
between strenuous field training and fitness testing.
3. Renal Complications of Sickle Cell Trait
3.1. Epidemiology of SCT and Chronic Kidney Disease
Renal abnormalities are among the best-recognized complications of SCT. It has been 
conclusively demonstrated that individuals with SCT have impaired urinary concentrating 
ability, albeit to a lesser degree than that seen in SCA (Gupta, et al 1991). In a large 
retrospective series of African-American males hospitalized in Veterans’ Administration 
facilities, haematuria was found to occur about twice as frequently (2.5% vs. 1.3%; p 
<0.001) among those with SCT than in those without (Heller, et al 1979). Numerous case 
reports and series have suggested that up to 50% of patients presenting for evaluation of 
haematuria may exhibit the more severe papillary necrosis (Li and Carroll 2014, Zadeii and 
Lohr 1997). Because of these associations, several studies have attempted to identify a 
relationship between SCT and kidney disease.
One of the first studies to evaluate SCT and its influence on renal disease was performed in 
a cohort of haemodialysis patients based in the Southeastern United States (Yium, et al 
1994). Six of 12 patients with polycystic kidney disease (PKD) as the cause of their end-
stage renal disease (ESRD) had concomitant SCT compared to 6 of 80 African-American 
patients with ESRD due to other causes. Furthermore, those with PKD and SCT initiated 
dialysis at a median age of 10 years younger than PKD patients without trait (p<0.003). 
These data suggest that sickle trait may accelerate the progression of PKD.
Other studies have evaluated surrogate markers of renal disease. A Brazilian study that 
compared SCA and SCT individuals with preserved renal function included 40 subjects with 
SCT. Microhaematuria was present in 30%, whereas microalbuminuria (which was felt to be 
more probably associated with evident renal disease) was present in 8% of individuals with 
SCT (Sesso, et al 1998). In another study assessing the presence of albuminuria, 181 Afro-
Caribbean individuals (34 with SCT) were recruited sequentially and in an unselected 
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fashion from patients with type 2 diabetes mellitus presenting to an outpatient clinic. Among 
these diabetic subjects, SCT was associated with a slightly greater likelihood of albuminuria 
(odds ratio 1.19) although this did not reach statistical significance (p=0.68) (Oli, et al 
2004). In contradistinction, another study of 52 Nigerian type 2 diabetics demonstrated that 
proteinuria (defined as >0.5 g/24 h) was more likely among those men with SCT than those 
without SCT (75.0% v. 21.7%, p<0.02). Women with SCT and diabetes were also more 
likely to have proteinuria, although the difference was less profound and was not statistically 
significant (25% v. 15.4%) (Ajayi and Kolawole 2004). In another group of 376 African-
Americans from a single centre, SCT was not associated with proteinuria, estimated 
glomerular filtration rate (eGFR) or a composite microvascular outcome that included end- 
stage kidney disease. SCT assessment in this group was derived from the same instrument 
used to perform Hb A1c testing. However, in this cohort proteinuria was missing in a large 
proportion of individuals, thereby limiting the analyses to some degree (Bleyer, et al 2010).
Recently, a number of studies have evaluated the prevalence of SCT in dialysis populations. 
In a single academic centre study of four dialysis units that included 188 African-American 
patients, SCT was identified in 14.9% compared to a prevalence of 7.1% in the background 
population as determined by newborn screening data (Derebail, et al 2010). A subsequent 
study of 1,085 African Americans with non-diabetic ESRD and 996 with type 2 diabetes-
associated ESRD compared these individuals to 1,177 controls. The prevalence of SCT was 
similar in each of the groups (in the range of 7.1% to 8.7%) (Hicks, et al 2011). However, a 
more recent study utilized data from a large national dialysis company, and ascertained the 
prevalence of SCT in 5,319 African-American ESRD patients. Within this cohort, 542 SCT 
subjects were identified, giving a prevalence of 10.2%, which was higher than the rates 
reported among population studies of African-Americans (6.5%-8.6%, p<0.001) (Derebail, 
et al 2014). All three of these studies were limited by their cross-sectional design; their 
inconsistent results suggest that the evaluation of prevalence of SCT in ESRD may not be 
the best approach to determine a link between SCT and renal disease.
Other studies have suggested a clearer association between SCT and kidney disease. 
Bucknor et al (2014) conducted a study of 13,462 African Americans enrolled in the Kaiser 
Permanente Northern California health system. Among these individuals, 2,642 were 
identified as having SCT, with >98% of those having confirmed laboratory profiles. In 
multivariate analyses, SCT was found to be associated with chronic renal disease (risk ratio 
1.13; 95% CI 1.03-1.23, p=0.008). However, outcomes in this study were limited by 
diagnostic determination that used International Classification of Diseases (ICD)-9 
diagnostic codes (Bucknor, et al 2014).
The most compelling data linking SCT and renal disease come from a large pooled 
population cohort study of nearly 16,000 African-Americans, in which the associations 
between SCT and various renal outcomes were evaluated (Naik, et al 2014a). The study 
cohort was derived from five population-based cohorts – the Atherosclerosis Risk in 
Communities Study (ARIC), the Women's Health Initiative (WHI), the Jackson Heart Study 
(JHS), the Multi-Ethnic Study of Atherosclerosis (MESA) and the Coronary Artery Risk 
Development in Young Adults (CARDIA). Each of the outcomes – CKD at any point in the 
studies, incident CKD, rapid eGFR decline (> 3ml/min/1.73 m2/year) and albuminuria - 
Key et al. Page 7













were assessed in each cohort individually and then pooled in a meta-analysis. These 
analyses were adjusted for age, sex, clinic or region, African genetic ancestry, diabetes and 
hypertension. For each outcome in each cohort, SCT demonstrated a consistent association, 
albeit with varying effect sizes. In the pooled analysis, for each cohort, SCT was statistically 
significant with each of the primary outcomes. Thus, for CKD, SCT demonstrated an odds 
ratio (OR) of 1.57 [95% CI, 1.34-1.84); for incident CKD, an OR of 1.79 (95% CI, 
1.45-2.20); and for decline in eGFR, an OR of 1.32 (95% CI, 1.07-1.61). SCT was also 
associated with albuminuria with an OR of 1.86 (95% CI, 1.49-2.31) (Naik, et al 2014a). 
Alternative definitions for CKD and continuous measures of eGFR and albuminuria were 
assessed in sensitivity analyses and demonstrated a consistent association. When stratified 
by diabetes, the association between SCT and incident CKD maintained a similar effect size. 
Each of these analyses also demonstrated that the influence of SCT on outcomes were 
independent of the APOL1 genetic risk variants, which are known to be associated with 
renal disease in African-Americans (Parsa, et al 2013). The consistency of the analyses 
among the individual cohorts and in sensitivity analysis is persuasive of an association 
between SCT and kidney disease, with an estimated population-attributable risk for incident 
CKD of about 6% (Naik, et al 2014a).
3.2. Potential underlying mechanisms of renal injury in SCT
While the link between SCT and kidney disease has arguably now been reasonably well 
established, only indirect data exist to explain the underlying pathophysiology. Certainly, 
the common manifestations of haematuria and impaired urinary concentration suggest injury 
to the renal medulla. The renal medulla provides a favourable environment in which sickling 
of RBCs may occur due to its high osmolality, high acidity and very low partial pressure of 
oxygen (10-20 mmHg) (Noguchi, et al 1981). Ischaemic injury from clinically silent 
episodes of sickling may play a role in ongoing renal injury and, in rare cases, progression to 
renal medullary carcinoma (Statius van Eps, et al 1970, Tsaras, et al 2009). Indeed, 
microradioangiographic studies performed on renal autopsy specimens of individuals with 
SCT demonstrate evidence of disruption and obliteration of the vasa recta (Statius van Eps, 
et al 1970). While not as severe as that seen in SCA, these studies suggest an intermediate 
vascular phenotype that is probably produced by repetitive ischaemic events. The drop out 
in these vessels could increase renal hypoxia, which has been shown to mediate further 
tubulointerstitial damage, fibrosis and subsequent loss of kidney function. A similar process 
has been hypothesized to drive progression of CKD, irrespective of cause. Those individuals 
with established CKD and SCT could be particularly susceptible to this self-perpetuating 
process of CKD-induced hypoxia and hypoxia-induced CKD progression (Fine and Norman 
2008, Nangaku 2006).
Just as in SCA, several potential modifiers may also play a role in the development of renal 
disease. The concomitant presence of α-thalassaemia has been shown to attenuate the 
severity of urinary concentration impairment (Gupta, et al 1991). Furthermore, a single 
report of a family of PKD patients with SCT and early onset of renal disease demonstrated 
these individuals to have the Central African Republic (CAR) haplotype of the HbS 
mutation (Kimberling, et al 1996). This haplotype has been previously demonstrated to lead 
to more severe outcomes in individuals with SCA, including kidney disease (Powars, et al 
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1994). Both haplotype and α-thalassaemia modulate the relative concentration of HbS, as 
well as the rheological properties of RBCs (Connes, et al 2014, Monchanin, et al 2005, 
Powars, et al 1994). Indeed, one may speculate that these genetic factors would influence 
sickling and ischaemic injury.
Studies on the mechanisms of renal disease in SCA have demonstrated that kidney injury is 
not simply driven by vaso-occlusion alone. Ischaemia-reperfusion injury, inflammation and 
oxidative stress from free haem, endothelial injury, nitric oxide deficiency and an underlying 
procoagulant state all play some role (Ataga, et al 2014, Nath 2012). Whether similar, albeit 
muted, processes of renal damage are in play in individuals with SCT remains unknown but 
certainly seem to be plausible avenues of future investigation. Additional information on 
whether co-inheritance of α-thalassaemia modulates the incidence and/or severity of renal 
disease (beyond hyposthenuria) would also be of interest.
3.3. Screening for SCT in the context of renal disease
Screening for SCT in individuals with kidney disease or determined to be at high risk for 
kidney disease is of unclear benefit (Cavanaugh and Lanzkron 2010). At present, no 
intervention exists to alter the course of progression of CKD specific to SCT. One could 
advocate that knowledge of SCT status and its increased risk may encourage adherence to 
non-specific CKD therapies, such as hypertension control, but presently, no data exist to 
guide screening. Certainly, if SCT status is known from prior screening (either neonatal, 
prenatal or as part of athletic screenings), this information could be helpful in outlining an 
overall risk profile for affected individuals. Similarly, whether screening for CKD, either by 
urinary albumin assessment or more frequent monitoring of renal function, is beneficial is 
unknown. With the recent data from Naik et al (2014a), an argument could be made for 
pursuing this course of action if the diagnosis of SCT is already established, but at what age 
and in which individuals this would be most helpful is also unknown.
In the setting of renal transplantation, screening for SCT has been the norm in some centres, 
although with a large degree of inconsistency between institutions. In a survey of US 
transplant centres, 83% of the 137 responding centres had no established policy for 
screening potential donors. In practice however, 34% did perform routine screening, and 
37% of centres excluded donors known to have SCT or if found to have SCT during 
screening (Reese, et al 2008). A single survey study performed in 1980 identified 21 SCT 
patients who received a renal transplant; it was concluded they had similar outcomes to the 
overall population (Chatterjee 1980). However, at present, there are limited data to guide 
policy on donor evaluation. Future studies utilizing retrospective data from SCT donors may 
be helpful in both determining allograft outcomes and donor outcomes. These data then 
could be used to inform the overall risk assessment of renal transplant evaluation.
3.4 Renal Medullary Carcinoma
A very rare complication of SCT is renal medullary carcinoma. This very aggressive 
malignancy has been reported almost exclusively in individuals with SCT (Davis, et al 
1995). In the original report of these malignancies, none were limited to the kidney at 
presentation and many were metastatic. Median survival after diagnosis was approximately 
Key et al. Page 9













4 months. These tumours often present in young people, with a median age of 26 years, and 
appear to have a male predominance at younger ages (Davis, et al 1995). These tumours 
appear to have a predilection for the right kidney and are associated with necrosis within the 
tumour, caliectasis and regional adenopathy (Blitman, et al 2005, Davis, et al 1995, Liu, et 
al 2013). The pathogenesis of renal medullary carcinoma remains unknown but it was 
originally thought to arise from the calyceal epithelium (Davis, et al 1995). Loss of 
SMARCB1 expression, responsible for repressing cyclin D1 transcription, has been 
described in these tumours, as have ALK re-arrangements (Liu, et al 2013, Marino-Enriquez, 
et al 2011). Presently, therapy of these lesions includes nephrectomy in the absence of 
metastatic disease and various chemotherapeutic regimens that have had limited success, 
with median survival still only six months (Maroja Silvino et al 2013), although there have 
been rare case reports of successful treatment (Gangireddy, et al 2012, Walsh, et al 2010). 
Therefore, early detection of these lesions is paramount and cross-sectional imaging of 
individuals with SCT presenting with haematuria is important for identifying these and other 
urothelial malignancies (Gill, et al 2012).
4. Sickle Cell Trait and Venous Thromboembolism
4.1. Epidemiology of SCT and VTE
An association between SCT and pulmonary embolism (PE) was first noted by Heller et al 
(1979) in their study of African-American Veterans’ Hospital discharges (2.2% incidence of 
PE vs. 1.5% in controls with normal haemoglobin profile; p<0.001). In another large case-
control study of African-Americans with VTE in Atlanta (the ‘GATE study’), SCT was 
shown to be a risk factor for VTE (OR = 1.8 (95% CI: 1.2-2.9)). This risk was particularly 
marked when considering PE (OR = 3.9 (95% CI: 2.2-6.9)) as opposed to DVT (Austin, et 
al 2007). Although a relatively modest risk factor overall, based on a population prevalence 
of SCT of 7-8%, the attributable risk of SCT in VTE among African-Americans was 
calculated to be higher than the attributable risk of the F2 (prothrombin gene) G20210A 
mutation in white Americans (≈7% vs. ≈3%, respectively) (Austin, et al 2007). In the 
previously mentioned study of more than 13,000 African-Americans enrolled in the Kaiser 
Permanente Northern California health system, an association of SCT with PE, but not 
DVT, was also noted (Bucknor, et al 2014). Finally, this association was confirmed in the 
ARIC prospective cohort study, where the hazard ratio (HR) for PE was 2.05 (95% CI, 
1.12-3.76), while the HR for DVT without PE was not significant at 1.15 (95% CI, 
0.58-2.27) (Folsom, et al 2014). Overall, therefore, the data consistently demonstrate that 
SCT is a modest risk factor for VTE, and in particular, PE. Whether or not co-inheritance of 
α-thalassaemia modulates the incidence of VTE is unknown.
4.2. Potential underlying mechanisms of VTE in SCT
The association between SCA and VTE has also only been recently documented. In parallel 
with SCT, the risk appears to be particularly elevated for PE rather than isolated DVT (Lim, 
et al 2013, Naik, et al 2014b, Novelli, et al 2012, Stein, et al 2006). Mechanistically, many 
more studies have evaluated the laboratory manifestations of activation of coagulation and 
platelets in SCA (Ataga and Key 2007, Lim, et al 2013) compared to SCT (Lawrie, et al 
2012, Westerman, et al 2002). Although it is premature to assume a common mechanism, 
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the proximal event is presumably related to the abnormal sickle haemoglobin. Therefore, it 
is tempting to speculate that, as with hypoxic exercising skeletal muscle or hypoxic acidotic 
renal medulla, the extremely low partial pressure of oxygen in the venous valve sinuses of 
the lower extremities (Hamer, et al 1981, Sevitt 1974), where DVT originates, may be 
sufficient to cause erythrocyte sickling and endothelial adhesion that initiates intravascular 
thrombosis (Brooks, et al 2009). In addition, the high blood viscosity frequently found in 
SCT may also promote thrombosis (Tripette, et al 2013). However, why PE is over-
represented compared to DVT in sickle haemoglobinopathies is not easily explained by 
these hypotheses. Possibilities include an increased risk of embolization, or possibly the 
formation of in-situ pulmonary artery thrombosis (Adedeji, et al 2001, van Langevelde, et al 
2012). Further mechanistic studies addressing this paradox are therefore needed.
4.3. Screening for SCT in the context of VTE
At present, no firm recommendation can be made for routine screening for SCT as part of a 
thrombophilia evaluation. Further studies are required to define whether SCT is a risk for 
recurrent VTE as it is for a first event, and whether there is any interaction with other risk 
factors, including pregnancy (Noubouossie and Key 2015, Pintova, et al 2013, Porter, et al 
2014) and hormonal contraceptive therapy use (Austin, et al 2009). Until these data are 
available, it seems prudent to view SCT as a weak risk factor for VTE, with 
recommendations that mirror those of other similar penetrance mutations, such as the F2 
G20210A mutation.
5. Implications of Defining Medical Complications of SCT
Given that newborn screening programmes for sickle haemoglobinopathies are now routine 
in many developed and developing countries, a greater appreciation of not only the scope, 
but also the underlying mechanisms of SCT-related complications will continue to be a 
prerequisite for accurate and appropriate counselling of affected individuals. At present, at 
least in the United States, counselling for subjects with SCT is purely focused on 
reproductive implications and choices. However, a consensus on any medical conditions for 
which carriers are at risk is an important public health priority, so that appropriate evidence-
based interventions (when available) can be enacted.
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